compani data secur llc estim reuter
compani data secur llc estim reuter
summari ew report revenu underli
ahead estim
consensu respect adj ep
report came our/consensu estim
replac sale came impress
consensu expect ew
tavr perform reflect procedur growth
us procedur growth ou teen europ
contribut transcathet mitral/tricuspid therapi tmtt
modest ew expect revenu
previous provid guidanc ew re-affirmed
top-lin guidanc growth
expect come around top rang addit ew
expect tavr sale around top previous
provid rang underli tavr growth nearli
bottom-lin ew increas ep
guidanc report
previous overal strong quarter driven
recent low risk approv ew updat guidanc
preliminari outlook appear conserv us
chang estim rais sale estim
underli adj ep estim
report rais sale
estim underli adj ep
estim report price target
base adj ep estim
tavr sale came well street expect
estim underli tavr growth
quarter comfort surpass estim
acceler ew
tavr perform compris procedur growth us
procedur growth ou teen europ
get insight ou market dynam
report earn novemb manag attribut
tavr market acceler sever potenti factor
awar borderlin patient receiv tavr fda
approv low-risk august addit result benefit
consumpt tax japan creat pull forward purchas
nearli stock quarter increas bill day vs
contribut quarter importantli
manag provid color tavr market call
return low double-digit global tavr procedur growth next year
consist estim market
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
tmtt remain modest contribut trim expect contribut
transcathet mitral/tricuspid therapi tmtt rel modest ew continu
focu physician train procedur success patient outcom launch pascal ou
 ew continu enrol clasp iid degen mitral regurgit pivot trial
initi enrol clasp iif function mitral regurgit pivot trial
replac side manag said continu pleas evoqu sapien earli
feasibl set remain track start sapien pivot trial end
tricuspid ew continu push pascal cardioband forward manag expect pascal go
pivot trial tricuspid set later year revenu perspect ew expect
less sale contribut tmtt expect previous
inspiri lead surgic structur heart ew report surgic structur heart ssh sale
underli slightli consensus/our estim respect
result driven continu adopt insipri surgic aortic valv partial off-set lower
surgic aortic valv replac savr procedur due tavr adopt expand
manag note inspiri valv util grew region continu see good traction
particularli among active/young patient regard harpoon ew said expect eu approv late
critic post solid quarter boost hemospher ew report critic cc sale
underli basic in-lin estimate/consensu result
driven strong perform across categori geographi bolster hemospher
casm integr fore-sight technolog hemospher continu progress well casm
contribut ew sale vs
top line rang re-affirmed tavr rais expect top rang ep guidanc
rais call ew re-affirmed top-lin guidanc rang growth
expect come around top rang ew rais tavr sale guidanc top end
expect previous expect tavr underli growth come
around nearli ew maintain underli target surgic
structur heart busi expect critic care includ casm come around
top-end underli regard currenc expect impact sale
fx remain headwind move ew expect gross margin
around ytd level impli averag gm sg spend sale unchang
 spend sale unchang tax rate ex special item bottom
previous issu rang bottom-lin ew rais ep guidanc
report appear larg reflect beat
revenu ep guidanc introduc ew guid sale
report compar prior consensu previou estim ew
ep guidanc report street expect previou
estim midpoint rang
earli thought issu guidanc manag provid high level
comment next year first mention manag believ tavr growth
low double-digit reflect previou estim market opportun ew
believ market slow mani procedur may pull
forward due awar expans tavr low risk approv creat bolu procedur
growth result compar difficult hurdl second manag
believ tmtt revenu doubl compar guidanc less bulk
pascal third ew believ gross profit guidanc robust given
number put take currenc compani hedg program benefit
price target
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
